冠状动脉疾病患者达标治疗策略与高强度他汀治疗的随机临床试验
该随机、多中心、非劣效性试验纳入韩国12中心4400例冠状动脉疾病患者,比较低密度脂蛋白胆固醇50-70 mg/dL达标策略与高强度他汀治疗。3年复合终点(死亡、心肌梗死、卒中或冠状动脉血运重建)达标组8.1% vs 高强度组8.7%,绝对差-0.6个百分点(单侧97.5%CI上限1.1个百分点),非劣效性P<.001。
要点
- 达标治疗组3年主要终点8.1%,高强度他汀组8.7%,绝对差-0.6个百分点。
- 非劣效性检验P<.001,非劣效界值为3.0个百分点。
- 达标组3年平均LDL-C为69.1 mg/dL,高强度组为68.4 mg/dL(P=.21)。
核心结论
- 在冠状动脉疾病患者中,以LDL-C 50-70 mg/dL为目标的达标治疗策略在3年死亡、心肌梗死、卒中或冠状动脉血运重建复合终点上非劣效于高强度他汀治疗。
- 这些发现为达标治疗策略的适用性提供了额外证据,该策略可能允许考虑他汀治疗反应的个体差异而进行量身定制。
研究设计与样本
- 随机、多中心、非劣效性试验,在韩国12个中心进行,入组时间2016年9月9日至2019年11月27日,最终随访2022年10月26日。
- 共纳入4400例冠状动脉疾病患者,4341例(98.7%)完成试验;平均(SD)年龄65.1(9.9)岁,女性1228例(27.9%)。
- 患者随机分配至LDL-C目标策略组(目标LDL-C 50-70 mg/dL,n=2200)或高强度他汀治疗组(瑞舒伐他汀20 mg或阿托伐他汀40 mg,n=2200)。
- 主要终点为3年死亡、心肌梗死、卒中或冠状动脉血运重建的复合终点,非劣效界值为3.0个百分点。
主要发现
- 达标治疗组(n=2200)有6449人年随访,其中43%使用中等强度他汀剂量,54%使用高强度他汀剂量。
- 3年平均(SD)LDL-C水平:达标治疗组69.1(17.8)mg/dL vs 高强度他汀组68.4(20.1)mg/dL(P=.21,与达标治疗组比较)。
- 主要终点事件:达标治疗组177例(8.1%)vs 高强度他汀组190例(8.7%),绝对差-0.6个百分点(单侧97.5%CI上限1.1个百分点);非劣效性P<.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In patients with coronary artery disease, some guidelines recommend initial statin treatment with high-intensity statins to achieve at least a 50% reduction in low-density lipoprotein cholesterol (LDL-C). An alternative approach is to begin with moderate-intensity statins and titrate to a specific LDL-C goal. These alternatives have not been compared head-to-head in a clinical trial involving patients with known coronary artery disease. OBJECTIVE: To assess whether a treat-to-target strategy is noninferior to a strategy of high-intensity statins for long-term clinical outcomes in patients with coronary artery disease. DESIGN, SETTING, AND PARTICIPANTS: A randomized, multicenter, noninferiority trial in patients with a coronary disease diagnosis treated at 12 centers in South Korea (enrollment: September 9, 2016, through November 27, 2019; final follow-up: October 26, 2022). INTERVENTIONS: Patients were randomly assigned to receive either the LDL-C target strategy, with an LDL-C level between 50 and 70 mg/dL as the target, or high-intensity statin treatment, which consisted of rosuvastatin, 20 mg, or atorvastatin, 40 mg. MAIN OUTCOMES AND MEASURES: Primary end point was a 3-year composite of death, myocardial infarction, stroke, or coronary revascularization with a noninferiority margin of 3.0 percentage points. RESULTS: Among 4400 patients, 4341 patients (98.7%) completed the trial (mean [SD] age, 65.1 [9.9] years; 1228 females [27.9%]). In the treat-to-target group (n = 2200), which had 6449 person-years of follow-up, moderate-intensity and high-intensity dosing were used in 43% and 54%, respectively. The mean (SD) LDL-C level for 3 years was 69.1 (17.8) mg/dL in the treat-to-target group and 68.4 (20.1) mg/dL in the high-intensity statin group (n = 2200) (P = .21, compared with the treat-to-target group). The primary end point occurred in 177 patients (8.1%) in the treat-to-target group and 190 patients (8.7%) in the high-intensity statin group (absolute difference, -0.6 percentage points [upper boundary of the 1-sided 97.5% CI, 1.1 percentage points]; P < .001 for noninferiority). CONCLUSIONS AND RELEVANCE: Among patients with coronary artery disease, a treat-to-target LDL-C strategy of 50 to 70 mg/dL as the goal was noninferior to a high-intensity statin therapy for the 3-year composite of death, myocardial infarction, stroke, or coronary revascularization. These findings provide additional evidence supporting the suitability of a treat-to-target strategy that may allow a tailored approach with consideration for individual variability in drug response to statin therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02579499.
引用
- Hong SJ, Lee YJ, Lee SJ, et al. Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. JAMA. 2023. PMID: 36877807. doi:10.1001/jama.2023.2487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。